Literature DB >> 26073032

Neurofibromatosis type 1 and malignancy in childhood.

A Varan1, H Şen1, B Aydın1, B Yalçın1, T Kutluk1, C Akyüz1.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary neurocutaneous syndrome characterized by multi-system involvement and an increased incidence of both benign and malignant tumors. In this study, we evaluated the clinical presentation and prognosis of NF1 and malignancy. Between 1975 and 2013, 26 (5%) of the 473 patients with NF1 at our center developed non-neurofibroma neoplasms. The patient files of 26 subjects with tumors, other than optic glioma, were analyzed retrospectively to evaluate clinical features and treatment results. The age at diagnosis of NF1 ranged from 3 months to 16 years (median 5.5 years). The age range at tumor diagnosis was 1.5-33 years (median 8 years) in these 26 patients. The tumor histological subtypes included the following: 12 soft-tissue tumors (6 malignant peripheral nerve sheath tumors (MPNST), 5 rhabdomyosarcomas (RMS) and 1 malignant fibrous histiocytoma), 11 brain tumors (6 low-grade gliomas, 3 high-grade gliomas, and 2 medulloblastoma), 2 neuroblastomas and 1 non-Hodgkin's lymphoma. Twelve of 26 patients were alive at the time of the study. Although benign brain tumors with NF1 are more common, high-grade brain tumors also occur. Thus, careful and regular follow-up is crucial for early detection of malignancy in NF1 patients.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  brain tumors; malignant peripheral nerve sheath tumors; neurofibromatosis; outcome

Mesh:

Year:  2015        PMID: 26073032     DOI: 10.1111/cge.12625

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  Hamartoma compress medial and radial nerve in neurofibromatosis type 1.

Authors:  Hui Lu; Qiang Chen; Hui Shen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Trametinib for progressive pediatric low-grade gliomas.

Authors:  Maria Kondyli; Valérie Larouche; Christine Saint-Martin; Benjamin Ellezam; Lauranne Pouliot; Daniel Sinnett; Geneviève Legault; Louis Crevier; Alex Weil; Jean-Pierre Farmer; Nada Jabado; Sébastien Perreault
Journal:  J Neurooncol       Date:  2018-08-10       Impact factor: 4.130

3.  Case series of congenital pseudarthrosis of the tibia unfulfilling neurofibromatosis type 1 diagnosis: 21% with somatic NF1 haploinsufficiency in the periosteum.

Authors:  Yu Zheng; Guanghui Zhu; Yaoxi Liu; Weihua Zhao; Yongjia Yang; Zhenqing Luo; Yuyan Fu; Haibo Mei; Zhengmao Hu
Journal:  Hum Genet       Date:  2022-01-13       Impact factor: 5.881

4.  An Exceptional Case of Intraparotid Plexiform Neurofibroma Originating from Autonomic Fibers of the Auriculotemporal Nerve.

Authors:  Sarantis Blioskas; Sotiris Sotiriou; Katerina Rizou; Triantafyllia Koletsa; Petros Karkos; Anna Kalogera-Fountzila; Konstantinos Markou
Journal:  Case Rep Med       Date:  2017-05-29

5.  Non-optic glioma in adults and children with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Jan M Friedman; Victor-Felix Mautner
Journal:  Orphanet J Rare Dis       Date:  2017-02-15       Impact factor: 4.123

6.  Pediatric malignancies in neurofibromatosis type 1: A population-based cohort study.

Authors:  Sirkku Peltonen; Roope A Kallionpää; Matti Rantanen; Elina Uusitalo; Päivi M Lähteenmäki; Minna Pöyhönen; Janne Pitkäniemi; Juha Peltonen
Journal:  Int J Cancer       Date:  2019-02-18       Impact factor: 7.396

Review 7.  Roles of mTOR Signaling in Brain Development.

Authors:  Da Yong Lee
Journal:  Exp Neurobiol       Date:  2015-09-17       Impact factor: 3.261

Review 8.  Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes.

Authors:  Orli Michaeli; Uri Tabori
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

9.  A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.

Authors:  Sébastien Perreault; Valérie Larouche; Uri Tabori; Cynthia Hawkin; Sarah Lippé; Benjamin Ellezam; Jean-Claude Décarie; Yves Théoret; Marie-Élaine Métras; Serge Sultan; Édith Cantin; Marie-Ève Routhier; Maxime Caru; Geneviève Legault; Éric Bouffet; Lucie Lafay-Cousin; Juliette Hukin; Craig Erker; Nada Jabado
Journal:  BMC Cancer       Date:  2019-12-27       Impact factor: 4.430

Review 10.  The Role of RUNX1 in NF1-Related Tumors and Blood Disorders.

Authors:  Youjin Na; Gang Huang; Jianqiang Wu
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.